Brookfield Corp’s Halozyme HALO Stock Holding History

Brookfield Corp’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36,500	Closed	-$2.08M	–	708
2022 Q4	$2.08M	Buy	+36,500	New	+$1.87M	0.01%	405

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Brookfield Corp's HALO Position: Q1 2023 in Review

Brookfield Corp sold out of Halozyme (HALO) in Q1 2023, closing a stake of 36,500 shares — an estimated $2.08M sold.

Brookfield Corp first reported a position in HALO in Q4 2022 and held it in 1 quarter. The position peaked at $2.08M in Q4 2022. 386 funds tracked by Wall St. Rank hold HALO as of Q1 2023.

Brookfield Corp reported no remaining Halozyme position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 36,500 Halozyme shares in Q1 2023, an estimated $2.08M.
Brookfield Corp first reported a position in Halozyme in Q4 2022 and held it in 1 quarter.
Brookfield Corp's Halozyme position peaked at $2.08M in Q4 2022.
386 funds tracked by Wall St. Rank held Halozyme as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.